Enveda
Founded Year
2019Stage
Series D | AliveTotal Raised
$535.5MValuation
$0000Last Raised
$150M | 2 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+77 points in the past 30 days
About Enveda
Enveda operates as a biotechnology company using artificial intelligence (AI) to assist in the development of medicines. The company identifies and characterizes a variety of molecules produced by living organisms, some of which have not been scientifically explored, creating a database of chemical biodiversity. The database is used by Enveda to address medical challenges. Enveda was formerly known as Enveda Therapeutics. It was founded in 2019 and is based in Boulder, Colorado.
Loading...
Loading...
Research containing Enveda
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Enveda in 4 CB Insights research briefs, most recently on Oct 28, 2025.
Oct 28, 2025 report
State of Digital Health Q3’25 Report
Sep 19, 2025 report
Book of Scouting Reports: AI Drug Discovery
May 23, 2025
The AI in drug R&D market map
Expert Collections containing Enveda
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Enveda is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,309 items
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Artificial Intelligence (AI)
20,894 items
AI in drug discovery
528 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Latest Enveda News
Nov 14, 2025
Growing interest in biopharmaceutical ventures and rising deal volume highlight expanding opportunities for strategic investment and innovation in this dynamic industry. Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Venture Capital Investment Trends in Pharma - Q3 2025" report has been added to ResearchAndMarkets.com's offering. This report analyzes the venture capital (VC) investment activity in Q3 2025 in the Pharma sector. In Q3 2025, the global pharma sector saw investments totaling $5 billion, marking an 9.9% increase from Q2 2025. Investment volume also rose, with 149 deals, representing a 10.4% uptick. Oncology emerged as the top therapy area with 69 deals backed by 231 investors. Scope This report provides an overview of VC investment activity globally in Q3 2025 in the Pharma sector involving biopharmaceutical drug companies. It identifies key trends, and the most notable deals announced in Q3 2025 in the Pharma sector. Reasons to Buy Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind. This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements. Key Topics Covered: 1 Table of Contents 2 Pharma Venture Capital Activity in Q3 2025 3 Global Investment Trends in Pharma 4 Global Quarterly Funding Activity in Pharma 5 Global VC Investment Trends for Biotechs 6 Notable Deals in Pharma 7 Global Mega Investments Trends in Pharma 8 Mega Investments Quarterly Funding Activity in Pharma 9 Global Investment Activity in Pharma by Deal Size 10 Global Investment Activity in Pharma by Deal Stages 11 Deal Activity in Pharma: Top Deal Stage Type Analysis 12 Pharma Regional Comparison - Q3 2025 13 Pharma Regional Investment Activity in Pharma by Value and Volume 14 Pharma Investment Review by Top 10 Countries 15 Top 10 Therapy Area Investment Review 16 Top Pharma Investors by Value in Q3 2025 17 Further Information Companies Featured MapLight therapeutics Kriya Therapeutics Odyssey Therapeutics Crystalys Therapeutics Treeline Biosciences Strand Therapeutics Enveda Biosciences Artbio Minghui Pharmaceutical (Shanghai) Co Star Therapeutics Avalyn Pharma Renasant Bio Ensoma Sparrow Pharmaceuticals Dualitas Therapeutics Setpoint Medical Charm Therapeutics For more information about this report visit https://www.researchandmarkets.com/r/cuuuz3 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Enveda Frequently Asked Questions (FAQ)
When was Enveda founded?
Enveda was founded in 2019.
Where is Enveda's headquarters?
Enveda's headquarters is located at 5700 Flatiron Parkway, Boulder.
What is Enveda's latest funding round?
Enveda's latest funding round is Series D.
How much did Enveda raise?
Enveda raised a total of $535.5M.
Who are the investors of Enveda?
Investors of Enveda include FPV Ventures, Kinnevik, Lux Capital, Level Ventures, Lingotto and 31 more.
Who are Enveda's competitors?
Competitors of Enveda include Brightseed and 5 more.
Loading...
Compare Enveda to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
BioSymetrics integrates clinical and experimental data with machine learning to develop precision medicines. The company focuses on target discovery and precision medicine development, using clinical data and in vivo validation to find new drug targets. BioSymetrics serves sectors involved in neurological, cardiometabolic, and rare disease research and drug development. It was founded in 2015 and is based in Huntington, New York. In February 2025, BioSymetrics was acquired by Renovaro BioSciences.
Nuritas engages in the discovery and development of bioactive peptides for various industries using artificial intelligence. Its offerings include peptide-based ingredients for dietary supplements, functional foods and beverages, medical foods, and cosmetics. The company serves the food and beverage, health and wellness, and cosmetics sectors with peptide solutions. It was founded in 2014 and is based in Dublin 2, Ireland.
Gandeeva Therapeutics is a medicine company that engages in drug discovery within the biotechnology sector. The company utilizes artificial intelligence and cryogenic electron microscopy to develop therapies that target protein interactions, particularly in oncology. Gandeeva Therapeutics collaborates and licenses technologies and has a team in structural biology, computer science, and medicinal chemistry. It was founded in 2021 and is based in Burnaby, Canada.
Pathos is a clinical-stage biotechnology focuses on the re-engineering of drug development using AI technologies. It provides services such as optimizing patient selection strategies and developing precision medicines. Pathos serves the biopharmaceutical industry by partnering to advance clinical-stage therapeutics. It was founded in 2022 and is based in Chicago, Illinois.
Metanovas focuses on health and beauty within the cosmetics, medical aesthetics, and functional foods sectors. The company specializes in developing nutraceutical and cosmeceutical products utilizing artificial intelligence and biotechnology to create products that enhance overall well-being. Metanovas collaborates with global brands to offer solutions in these areas. It was founded in 2021 and is based in Foster City, California.
Loading...